Integration of an EEG biomarker with a clinician's ADHD evaluation.

ABSTRACT:

Background

This study is the first to evaluate an assessment aid for attention-deficit/hyperactivity disorder (ADHD) according to both Class-I evidence standards of American Academy of Neurology and De Novo requirements of US Food and Drug Administration. The assessment aid involves a method to integrate an electroencephalographic (EEG) biomarker, theta/beta ratio (TBR), with a clinician's ADHD evaluation. The integration method is intended as a step to help improve certainty with criterion E (i.e., whether symptoms are better explained by another condition).

Methods

To evaluate the assessment aid, investigators conducted a prospective, triple-blinded, 13-site, clinical cohort study. Comprehensive clinical evaluation data were obtained from 275 children and adolescents prese

SUBMITTER: Snyder SM 

PROVIDER: S-EPMC4356845 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature